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Abstract 
Review on PHLDA3, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords 
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Identity 
Other names: TIH1 
HGNC (Hugo): PHLDA3 
Location: 1q32.1 
Location (base pair) 
Starts at 201464284 and ends at 201469171 bp from 
pter (GRCh38.p12 - 21/12/2017) 
Note 
PHLDA3 was mapped to human chromosome 
1q32.1 and consist of 4,888 base pairs, starting at 
base pair 201464284 and ending at base pair 
201469171 from the p-terminus, it is a TP53 
responsive gene and is required for TP53-dependent 
apoptosis (Frank et al., 1999; Kawase et al., 2009). 
This gene is a member of the Pleckstrin Homology-
Like Domain A family, which includes PHLDA1, 
PHLDA2, and PHLDA3. PHLDA3 downregulation 
has been correlated with DNA hypermethylation in 
some types of cancer as prostate (Mahapatra et al., 
2012) and neuroendocrine tumors, and also with 
TP53 mutation in neuroendocrine tumors and 
mammary carcinomas (Ohki et al., 2014; Takikawa 
and Ohki, 2017; Christgen et al., 2012; Leszczynska 
et al., 2015). The DNA of PHLDA3  
contains 3 exons and encodes a 2.74 kb mRNA with 
a coding region of 383bp. 
DNA/RNA 
Description 
DNA size: 4,888 kb; 3 exons 
Transcription 
mRNA size: 2734bp   NM_012396.4. Three 
transcript variants encoding different isoforms and 
three non-coding transcripts variants have been 
descript for this gene.  
NM_012396 - Homo sapiens pleckstrin homology-
like domain, family A, member 3 (PHLDA3), 
transcript variant 1, mRNA-> NP_036528. 
Transcript size: 2734bp. Translation length: 127 
residues. 
https://www.ncbi.nlm.nih.gov/nuccore/NM_012396
.4 - 28 May, 2015. Variant 1 encodes the functional 
protein.  
NR_073080 - Homo sapiens pleckstrin homology 
like domain family A member 3 (PHLDA3), 
transcript variant 2, non-coding RNA. Transcript 
size: 1625 bp. 
https://www.ncbi.nlm.nih.gov/nuccore/NR_073080.
1 - 23 - Dec - 2018 
ENST00000367311.4 - Homo sapiens pleckstrin 
homology like domain family A member 3 
(PHLDA3), transcript variant, protein coding, 
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mRNA -> NP_036528, NM_012396. Transcript 
size: 2640 bp Translation length: 127 residues. 
http://www.ensembl.org/id/ENST00000367311.4  
ENST00000367309.1 - Homo sapiens pleckstrin 
homology like domain family A member 3 
(PHLDA3), transcript variant, protein coding. 
Transcript size: 896 bp. Translation length: 127 
residues. 
http://www.ensembl.org/id/ENST00000367309.1 
ENST00000485436.1 - Homo sapiens pleckstrin 
homology like domain family A member 3 
(PHLDA3), transcript variant, non-coding RNA. 
Transcript size: 661 bp. 
http://www.ensembl.org/id/ENST00000485436.1 
ENST00000497057.1 - Homo sapiens pleckstrin 
homology like domain family A member 3 
(PHLDA3), transcript variant, non-coding RNA. 
Transcript size: 582 bp. 
http://www.ensembl.org/id/ENST00000497057.1 
Protein 
NP_036528.1. Molecular weight: 13.9 kDa, 127 aa. 
https://www.ncbi.nlm.nih.gov/protein/NP_036528.
1 - 23/Dec/18 
Figure 1. Schematic representation of the PHLDA3 
protein structure.  The structure of the PHLDA3 protein is 
composed mainly of the pleckstrin like-domain (PHL). 
Description 
PHLDA3 is a 13.9kDa protein, composed of 127 
amino mostly comprised of the PHL domain (120aa) 
(Frank et al., 1999). PHLDA3 PHL domain confers 
to this protein the ability of binding specifically to 
membrane lipids. According to in vitro binding 
assay, PHLDA3 protein binds to a wide combination 
of phosphatidylinositol  
phosphate (PIP): (PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, 
PI(4,5)P2, PI(3,5)P2 and PI(3,4,5)P3) (Kawase et 
al., 2009; Saxena et al., 2002). PHLDA3 has been 
reported as an AKT1 (Akt) pathway inhibitor and 
associated with tumor suppression (Kawase et al., 
2009). 
Expression 
A RNA-seq performed in different tissue samples 
shown that PHLDA3 is broadly expressed in adrenal, 
appendix, brain, colon, duodenum, endometrium, 
esophagus, fat, gall bladder, heart, kidney, liver, 
lung, lymph node, ovary, pancreas, placenta, 
prostate, salivary gland, skin, small intestine, spleen, 
stomach, testis, thyroid and urinary bladder tissue 
(Fagerberg et al., 2014). PHLDA3 expression has 
been shown to be modulated by promoter 
methylation in prostate cancer and TP53 mutations 
in human infiltrating lobular breast cancer cells 
(Christgen et al., 2012; Mahapatra et al., 2012). Also, 
besides TP53 it was described that XBP1 
transcription factor is implicated in PHLDA3 
induction upon ER stress (Han et al., 2016).  
PHLDA3 was identified as a gene modulated by 
ochratoxin A (OTA) induced genotoxicity, it was 
upregulated in renal outer medulla cells after 
treatment with the renal carcinogen OTA in response 
to DNA damage. In other toxicogenomics studies, 
PHLDA3 was also proposed as a potential biomarker 
(Ellinger-Ziegelbauer et al., 2008; Furihata et al., 
2018; Hibi et al., 2013; Uehara et al., 2008). 
Localisation 
PHLDA3 is primarly localized at the plasmatic 
membrane due its specificity binding to membrane 
phosphoinositides but can also be find in the 
cytoplasm and extracellular content. 
 
Figure 2 - Schematic diagram of the modulators and biological effects of PHDA3 expression. PHLDA3 is a p53-target 
gene activated in response to DNA damage and hypoxia. The gene can also be activated by Xbp1 in response to endoplasmic 
reticulum stress (ER stress). PHLDA3 induction leads to Akt pathway inhibition by binding to phosphoinositide competition 
leading to increased apoptosis and proliferation, and decreased cell reprograming efficiency. 
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Function 
Murine PHLDA3 was first identified in 1999 and 
was designated Tih1 as the closest paralog of the 
imprinted gene Ipl (Frank et al., 1999). It was 
reported as a tumor suppressor gene. PHLDA3 
protein function is still being studied, but it was 
reported as an AKT1 (Akt) pathway repressor by 
preventing Akt-binding to membrane lipids. Thus, 
PHLDA3 is a TP53 regulated repressor of Akt 
signaling by binding competition, so inhibits Akt 
activity via competitive binding to PIP3 (Kawase et 
al., 2009) and thereby acts as a dominant-negative 
form of Akt contributing to TP53-dependent 
apoptosis. It was reported that active TP53 localizes 
to the transcription start site of PHLDA3 and 
transcriptionally activates this gene. PHLDA3 was 
upregulated by hypoxia (Leszczynska et al., 2015), 
and there is a clear accumulation of TP53 at the 
response elements identified in PHLDA3, 
demonstrating direct transactivation of these genes 
in response to hypoxia in colorectal carcinoma, non-
small-cell lung carcinoma, and nontumor lung 
fibroblast cells. It was observed after cisplatin 
treatment in testicular germ cell-derived human 
embryonal carcinoma cells that PHLDA3 and other 
genes downstream targets of TP53 are involved in 
response to DNA damage and events leading to cell 
death (Kerley-Hamilton et al., 2005).  
In renal tubular cells, cisplatin increases PHLDA3 in 
kidneys' tubules and in urinary content suggesting 
PHLDA3 protein as a kidney injury marker since it 
is urine-detectable (Lee et al., 2014; Lee, Kang, and 
Kim 2015).  
Furthermore, PHLDA3 exhibited statistically 
significant changes in gene expression in liver 
samples of rats treated with genotoxic 
hepatocarcinogens, suggesting that it may be a 
candidate marker gene for differentiating genotoxic 
hepatocarcinogens from non-genotoxic 
hepatocarcinogens (Suenaga et al., 2013). There is 
evidence that PHLDA3 is involved in zebrafish 
embryogenesis since PHLDA3 overexpression 
disrupted hemangioblast specification and affected 
intersegmental vessel development (ISV). It was 
suggested that overexpression of PHLDA3 inhibits 
ISV development by blocking the activation of AKT, 
it is supported by data showing a reversal of ISV 
defects induced by phlda3 overexpression upon Akt 
constitutively active form expression (Wang et al., 
2018). In induced pluripotent stem cells (iPSC) 
PHLDA3 was expressed at a lower level and reduced 
gradually during the process of iPSCs generation; 
reprogramming efficiency was inhibited by 
PHLDA3 overexpression. Evidence supports that the 
mechanism by which PHLDA3 promotes decrease 
iPSC generation efficiency involves Akt- GSK3B 
activation during the reprogramming process (Qiao 
et al., 2017). Photoreceptor injury induced PHLDA3 
expression in microglia, the resident macrophage in 
the CNS, data provide insights into the participation 
of PHLDA3 in the activation status of microglia 
under pathological conditions (Koso et al., 2016). 
PHLDA3 was the most significantly affected gene 
by thrombin knockout in zebrafish embryos but 
PHLDA3 function in embryonic development is still 
unclear (Day and Jagadeeswaran, 2009).  
The process of endomitosis consists of several 
rounds of DNA synthesis without division and 
leading to polyploidization in megakaryocytes. 
Downregulation of TP53-target genes in TP53 
knock-down megakaryocytes supports the 
hypothesis that TP53 suppresses polyploidization 
during megakaryocytic differentiation by arresting 
DNA synthesis and inducing apoptosis. PHLDA3 
together with other genes was identified as a gene 
through which TP53 mediates these biological 
effects in megakaryocytes (Apostolidis et al., 2012). 
Homology 
PHLDA3 gene is highly conserved in Euteleostomi 
and homologs have been found in P.troglodytes, 
M.mulatta, M.musculus, R.norvegicus, G.gallus and 
D.rerio. 
Implicated in 
Tumor suppressor 
PHLDA3 represses Akt activity and Akt-regulated 
biological processes including insulin-mediated 
glucose transport, protein and glycogen synthesis, 
proliferation, cell growth, differentiation, and 
survival. Pancancer genomics analyses of human 
cancer shown that TP53 mutation is significantly 
related to PHLDA3, TNFRSF10B and PTEN 
downregulation. Thus, a TP53 mutation may cause 
tumor development due to the loss of basal TP53 
target expression together with the TP53 mutant 
inability to active stress-responsive genes as 
PHLDA3 (Pappas et al., 2017). PHLDA3 suppresses 
neuroendocrine tumorigenicity and deficiency of 
this gene results in islet resistance to oxidative stress 
leading to increased proliferation, cell death 
prevention and improved insulin-releasing function 
without causing tumors. It was also observed in 
PHLDA3-deficient islet enhanced activation of Akt 
in response to hypoxia, thereby inducing signaling 
pathways of apoptosis inhibition, and cellular 
growth and survival (Sakata et al., 2017). It was 
observed after cisplatin treatment in testicular germ 
cell-derived human embryonal carcinoma cells that 
PHLDA3 and other genes downstream targets of 
TP53 are involved in response to DNA damage and 
events leading to cell death (Kerley-Hamilton et al., 
2005). PHLDA3 was identified as a gene modulated 
by ochratoxin A (OTA) induced genotoxicity, it was 
upregulated in renal outer medulla cells after 
treatment with the renal carcinogen OTA in response 
PHLDA3 (Pleckstrin Homology-Like Domain, family A, 
member 3) 
Ferreira MP, Nagai MA 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2020; 24(1) 11 
 
to DNA damage. In other toxicogenomics studies, 
PHLDA3 was also proposed as a potential biomarker 
(Uehara et al., 2008;  Ellinger-Ziegelbauer et al., 
2008; Hibi et al., 2013; Furihata et al., 2018). 
Fusion genes  
PHLDA3/ MYBPH (1q32.1/1q32.1). Cancer type: 
Breast Cancer (FusionGDB ID: 26994).  
PHLDA3/ PFKM (1q32.1/ 12q13.11) Cancer type 
NOS (FusionGDB ID: 26995). 
Prostate cancer 
The association of PHLDA3 and prognosis of cancer 
patients is still under investigation. Some studies 
have found that downregulation of PHLDA3 in 
cancer worsens the prognosis of patients diagnosed 
with cancer. In prostate cancers, for example, 
reduced expression of PHLDA3 is found in 22% of 
the patients in the study. Furthermore, microarray 
analysis performed to evaluate the global 
methylation profiling of prostate cancer patients with 
clinical recurrence revealed significant DNA 
methylation of PHLDA3 in the patients with clinical 
recurrence (Mahapatra et al., 2012). 
Solid cancers (prostate cancer, 
breast cancer, pancreatic cancer and 
lung neuroendocrine tumors, lung 
cancer, gastric cancer, melanoma, 
sarcomas, ovarian cancer, and 
colorectal cancer). 
Prognosis:  
The association of PHLDA3 and prognosis of cancer 
patients is still under investigation. Some studies 
have found that downregulation of PHLDA3 in 
cancer worsens the prognosis of patients diagnosed 
with cancer. Microarray analysis to evaluate a global 
methylation profiling of prostate cancer patients with 
clinical recurrence revealed significant DNA 
methylation of PHLDA3 in the patients with clinical 
recurrence (Mahapatra et al 2012).  
In silico analysis using Oncomine datasets showed 
that underexpression of PHLDA3 together with 
INPP5D, SULF2, BTG2, CYFIP2 and KANK3, a 
hypoxia-inducible TP53-dependent group of genes, 
was significantly associated with a poor clinical 
outcome in patients with breast, lung, gastric, 
melanoma, sarcoma, ovarian, and colorectal cancers. 
Individually no relation of their expression with 
patient prognosis was observed, suggesting that their 
concomitant regulation is the relevant factor for 
clinical outcome in these tumors. A meta-analysis on 
METABRIC data confirmed that lower expression 
of these group of genes correlated with TP53 
mutation status and was associated with poor patient 
outcome in overall survival over 12 years in breast 
cancer patients (Leszczynska et al., 2015).  
Furthermore, PHLDA3 downregulation was 
consistently observed in cells with PHLDA3 LOH 
and associated with pancreatic neuroendocrine 
tumors at an advanced stage, whereas lack of LOH 
was related to lower tumor grades (Ohki et al., 2014; 
Takikawa  Ohki, 2017).  
Also, loss of PHLDA3 associated with protein 
expression downregulation is frequently found in 
primary lung cancer (Kawase, T. et al., 2009).  
Reduced expression of PHLDA3 is also found in 
22% of prostate cancers (Soung, et al., 2011). 
Furthermore, Low PHLDA3 expression is associated 
with poor prognosis and postoperative tumor 
progression and recurrence in patients with 
oesophageal squamous cell carcinoma (ESCC) 
(Muroi, et al., 2015). 
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